The study tested the effects of balcinrenone/dapagliflozin, a combination drug, in different conditions: fasted, fed, and with the P-gp inhibitor quinidine. The goal was to understand how these ...

The announcement of this study could positively influence AstraZeneca’s stock performance and investor sentiment, given the potential for BGF MDI to become a significant treatment option for COPD.

Stephanie Ewens By Sonia Waraich – Staff writer, Triangle Business Journal Jul 6, 2021 Updated Jul 8, 2021 12:48pm EDT ...

PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of expertise-based contract research, consulting, medical communications, and ...

PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of expertise-based clinical research, consulting, medical communications, and ...

Parexel International Corp., a research organization that does subcontracting work for biotech companies, plans to cut between 1,100 and 1,200 jobs worldwide in an expansion of a restructuring ...

The partnership between Parexel and Sanofi will explore the potential of wearables in a pilot study. The study will specifically look at Parexel's Perceptive MyTrials - a clinical trial data ...

Parexel is one of the largest CROs in the world and is listed on ClinicalTrials.gov as participating in 65 studies that are enrolling patients, active or set to begin recruiting.

EQT AB and Goldman Sachs Group Inc.’s investment arm agreed to buy contract-research organization Parexel International Corp. for $8.5 billion, including debt. Parexel runs clinical trials and ...

PAREXEL Consulting's analysis reveals that there are other factors pointing to a "new normal." "The FDA's 13 percent priority designation rate for 2009 new drug applications mirrors the low rate ...

Parexel also raised its earnings expectations slightly for its fiscal 2013, which ends June 30, 2013, to between $1.675 to $1.695 billion (from $1.630 to $1.660 billion).

Drug-research services provider Parexel International Corp. is exploring a sale, according to people familiar with the matter. The company is working with investment bankers to sound out potential ...